| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.02 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.02 |